Pfizer Ceases Sale Of Children’s Vaccine In China

Agence France-Presse: Pfizer stops sale of children’s vaccine in China
“American pharmaceutical giant Pfizer has stopped selling one of its lucrative vaccines for children in China, the company said. Pfizer gave no explanation for stopping its sales of the Prevnar vaccine, which helps prevent infections such as pneumonia, which killed an estimated 935,000 children under the age of five globally in 2013, according to the World Health Organization…” (4/4).

Financial Times: Pfizer halts China vaccine sales after import license not renewed
“U.S. drugmaker Pfizer has halted vaccine sales in China after an import license for one of its top-selling treatments expired, dealing a blow to the company’s business and potentially creating a vaccine shortage for Chinese toddlers…” (Wildau, 4/3).

Wall Street Journal: Pfizer to Cease Vaccine Sales Business in China
“…Pfizer, the only company selling the drug in China, anticipates a shortage of the vaccine there, the statement said. … China has also faced vaccine shortages in the past. Regulators weren’t immediately available for comment on shortages and backlog matters. Pfizer’s global sales of Prevenar-branded products reached $4.5 billion in 2014, up 12 percent, up from a year earlier” (Burkitt, 4/2).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.